COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study
Abstract
Coronavirus disease 2019 (COVID-19) has been associated with an increased thrombotic risk, potentially exacerbated in patients with active cancer. We conducted a retrospective cohort study including 119 cancer patients with COVID-19 and 214 matched prepandemic controls. Patients with COVID-19 had poorer performance status and were more frequently treated with palliative intent. After a median follow-up of 32.7 months, overall thrombotic event rates did not differ between groups. However, after adjustment for clinically relevant covariates and accounting for death as a competing event, COVID-19 status and palliative treatment intent remained independently associated with a higher cumulative incidence of thrombotic events. In conclusion, COVID-19 may increase thrombotic risk in patients with cancer and occurs more frequently in patients with poorer clinical status. These findings are exploratory and require confirmation in larger prospective studies.
Related
- Viscoelastic Testing for Assessment of Hypercoagulability and Thrombotic Risk in Cancer Patients: A Systematic Review
- CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY
- Assessing the Influence of Propofol Sedation Versus Propofol-Free Sedation on Recovery From Sepsis and Septic Shock in Mechanically Ventilated ICU Patients: A Retrospective, Propensity-Score Matched, Cohort Study
- One-year cancer incidence following acute ischemic stroke: a retrospective propensity-matched multi-center cohort study
- Risk Factors and Subtype-Specific Prediction Models for Arterial versus Venous Thrombotic Events in Chinese Patients with Lupus Nephritis: A Retrospective Cohort Study
BibTeX
@article{doyen2026covid19,
title = {{COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study}},
author = {Jérôme Doyen and Alexandre Lacour and Renaud Schiappa and Eva Seutin and Amanda Garrido and Tanguy Pace Loscos and Denis Doyen},
journal = {JNCI Cancer Spectrum},
year = {2026},
month = oct,
doi = {10.1093/jncics/pkag110},
url = {https://doi.org/10.1093/jncics/pkag110},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study
AU - Jérôme Doyen
AU - Alexandre Lacour
AU - Renaud Schiappa
AU - Eva Seutin
AU - Amanda Garrido
AU - Tanguy Pace Loscos
AU - Denis Doyen
PY - 2026
DA - 2026/10/12
JO - JNCI Cancer Spectrum
DO - 10.1093/jncics/pkag110
UR - https://doi.org/10.1093/jncics/pkag110
AB - Coronavirus disease 2019 (COVID-19) has been associated with an increased thrombotic risk, potentially exacerbated in patients with active cancer. We conducted a retrospective cohort study including 119 cancer patients with COVID-19 and 214 matched prepandemic controls. Patients with COVID-19 had poorer performance status and were more frequently treated with palliative intent. After a median follow-up of 32.7 months, overall thrombotic event rates did not differ between groups. However, after adjustment for clinically relevant covariates and accounting for death as a competing event, COVID-19 status and palliative treatment intent remained independently associated with a higher cumulative incidence of thrombotic events. In conclusion, COVID-19 may increase thrombotic risk in patients with cancer and occurs more frequently in patients with poorer clinical status. These findings are exploratory and require confirmation in larger prospective studies.
SN - 2515-5091
ER -